Product Description.:
M 52
tablet , white , scored , round round
Biconvex
Visken ? (pindolol), a synthetic beta-adrenergic receptor blocking agent with intrinsic sympathomimetic activity is 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol.
Pindolol is a white to off-white odorless powder soluble in organic solvents and aqueous acids. Visken ? (pindolol) is intended for oral administration.
5 mg and 10 mg Tablets
Active Ingredient: pindolol
Inactive Ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.
INDICATIONS
Visken ? (pindolol) is indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.
DOSAGE AND ADMINISTRATION
The dosage of Visken ? (pindolol) should be individualized. The recommended initial dose of Visken? (pindolol) is 5 mg b.i.d. alone or in combination with other antihypertensive agents. An antihypertensive response usually occurs within the first week of treatment. Maximal response, however, may take as long as or occasionally longer than 2 weeks. If a satisfactory reduction in blood pressure does not occur within 3-4 weeks, the dose may be adjusted in increments of 10 mg/day at these intervals up to a maximum of 60 mg/day.
SIDE EFFECTS
Most adverse reactions have been mild. The incidences listed in the following table are derived from 12-week comparative double-blind, parallel design trials in hypertensive patients given Visken ? (pindolol) as monotherapy, given various active control drugs as monotherapy, or given placebo. Data for Visken? (pindolol) and the positive controls were pooled from several trials because no striking differences were seen in the individual studies, with 1 exception. When considering all adverse reactions reported, the frequency of edema was noticeably higher in positive control trials [16% Visken? (pindolol) vs. 9% positive control] than in placebo controlled trials [6%Visken? (pindolol) vs. 3% placebo]. The table includes adverse reactions either volunteered or elicited, and at least possibly drug related, which were reported in greater than 2% of Visken? (pindolol) patients and other selected important reactions.